Tarceone Tab. (Erlotinib)

Lipid, Amino acids and GlucoseTotal Parenteral Nutrition product, Emulsion for intravenous nutrition

Pleural mesothelioma and non-small cell lung cancer

Fixed Dose Combination drug, indicated for Gastroduodenal ulcer, gastritis, reflux esophagitis

Fixed Dose Combination drug, indicated for Hyperlipidemia Primary hypercholesterinemia with Clinical trials phase Ⅰ & Ⅲ

Insomnia, Non-addictive and helps staying asleep longer

Serious infections by gram-positive bacteria

Serious, life-threatening infections by gram-positive bacteria

Overactive bladder

Tegoprazan is a novel patented Potassium-Competitive Acid Blocker (P-CAB) which alleviates the limitations of the historical Proton Pump Inhibitors (PPIs) and of other competing P-CABs. 

Tegoprazan's competitive advantages have been demonstrated via Phase 3 clinical studies conducted in Korea a...

Fixed Dose Combination drug, indicated for Type2 Diabetes with Hyperlipidemia with Clinical trials phase Ⅰ & Ⅲ

Colorectal cancer

Chronic myelogenous leukemia and acute lymphocytic leukemia

Korean pharmaceutical firm HK inno.N Corp. said on Friday that its gastroesophageal reflux disease drug K-CAB has been approved by the Ministry of Food and Drug Safety, marking the first time for the company to launch an independently-developed novel drug under its name. HK inno.N plans to advance into overseas markets with its first novel drug, which has already been licensed out to China’s Shandong Luoxin Pharmaceutical Group in a 100 billion won ($89.7million)